Boston Scientific to Acquire Nalu Medical for $533M, Expanding Its Chronic Pain Treatment Portfolio

Marlborough, MA, October 17, 2025 (PRNewswire) -- Boston Scientific has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medtech company specializing in minimally invasive neurostimulation therapies for chronic pain.

Boston Scientific, an early investor in Nalu since 2017, will pay approximately $533 million in cash for the remaining equity. Nalu’s FDA-cleared Neurostimulation System uses peripheral nerve stimulation (PNS) to relieve severe chronic pain by delivering mild electrical impulses that block pain signals before they reach the brain. The miniature, battery-free implant is powered wirelessly by an external therapy disc and controlled via a smartphone app.

Clinical trials (COMFORT and COMFORT 2) showed compelling results—up to 87% of patients reported more than 50% pain reduction after 12 months, and real-world data from over 2,000 users confirmed durable benefits across multiple chronic pain conditions.

"Peripheral nerve stimulation addresses a major unmet need," said Jim Cassidy, president of Neuromodulation at Boston Scientific. "The addition of Nalu’s differentiated technology strengthens our pain management portfolio and expands access to innovative care options."

The deal is expected to close in the first half of 2026, with Nalu projected to surpass $60 million in 2025 sales and grow more than 25% year-over-year in 2026. The acquisition will be EPS accretive from 2027 onward on an adjusted basis.

Read full article here.